by Andreas Kremer | Jun 1, 2022
EU-PEARL is a strategic partnership between the public and private sectors to shape the future of clinical trials. This innovative and challenging enterprise aims to create a framework for patient-centric integrated research platform (IRP) trials, through which novel...
by Andreas Kremer | Nov 15, 2021
OPTIMA aims to harness the power of artificial intelligence, to advance treatments and facilitate decision-making for physicians and patients with prostate, breast and lung cancer. At the heart of OPTIMA will be Europe’s first interoperable, large scale oncology data...
by Lisa Blum | Oct 6, 2021
Myeloid immune cells are important mediators in the pathology of many diseases, especially in diseases associated with chronic inflammation (DACI). Recent advancements in molecular profiling technologies have led to the generation of large data sets, many of those not...
by Lisa Blum | Feb 3, 2021
Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative novel treatment that has the potential to cure cancer. Multiple new versions of this therapy are being developed for distinct...
by Lisa Blum | Feb 24, 2020
The project ImmUniverse has been formed as a European transdisciplinary consortium to tackle these unmet needs and to understand the role of the crosstalk between tissue microenvironment and immune cells in disease progression and response to...
